87 PAPILLARY RENAL CELL CARCINOMA WITH LOSS OF 9P: A LETHAL GENOTYPE

You have accessJournal of UrologyKidney Cancer: Basic Research I1 Apr 201087 PAPILLARY RENAL CELL CARCINOMA WITH LOSS OF 9P: A LETHAL GENOTYPE Tobias Klatte, Nagesh Rao, Jonathan Said, Michela de Martino, Brian Shuch, Nazy Zomorodian, Fairooz Kabbinavar, Arie Belldegrun, and Allan Pantuck Tobias KlatteTobias Klatte More articles by this author , Nagesh RaoNagesh Rao More articles by this author , Jonathan SaidJonathan Said More articles by this author , Michela de MartinoMichela de Martino More articles by this author , Brian ShuchBrian Shuch More articles by this author , Nazy ZomorodianNazy Zomorodian More articles by this author , Fairooz KabbinavarFairooz Kabbinavar More articles by this author , Arie BelldegrunArie Belldegrun More articles by this author , and Allan PantuckAllan Pantuck More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.135AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Cytogenetic analyses have emerged as a prognostic tool for patients with renal cell carcinoma. Whereas multiple studies identified loss of 9p as an unfavorable prognostic factor for patients with clear cell renal cell carcinoma, its role in papillary renal cell carcinoma (PRCC) is largely unknown. The aim of this study was to evaluate the prognostic impact of 9p loss in PRCC. METHODS We prospectively studied 65 patients who underwent surgery for PRCC at UCLA. For cytogenetic analysis, viable tumor samples were collected immediately after surgery, short-term cultured and analyzed by using the GPG banding technique. Fifty-seven tumors showed an abnormal karyotype and form the principal study cohort. The primary point of interest was disease-specific survival. RESULTS Loss of 9p occurred in six tumors and included three terminal deletions, one numerical loss of chromosome 9 and one unbalanced translocation. Loss of 9p was associated with higher T stages (p=0.001) and metastatic disease (p=0.002). After a mean follow-up of 25 months, all six patients with loss of 9p had died from PRCC, but only 6 out of 51 (12%) without loss of 9p (p<0.001). Median survival time of patients with loss 9p was only 6 ± 2 months. In multivariate analysis, however, loss of 9p was not retained as an independent prognostic factor (p=0.249). CONCLUSIONS Similar to clear cell RCC, PRCCs with loss of 9p are associated with aggressive pathological characteristics and poor prognosis. Therefore, these tumors should be treated aggressively with surgery followed by close surveillance. Association with prognosis implies the loss of tumor suppressor genes on 9p during PRCC progression. Los Angeles, CA© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e36 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Tobias Klatte More articles by this author Nagesh Rao More articles by this author Jonathan Said More articles by this author Michela de Martino More articles by this author Brian Shuch More articles by this author Nazy Zomorodian More articles by this author Fairooz Kabbinavar More articles by this author Arie Belldegrun More articles by this author Allan Pantuck More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...